Mild Cognitive Impairment and Psychopathology (MIND)

Mild Cognitive Impairment and Psychopathology: Effects on Awareness, Social Life, and Work. Cross-sectional Observational Study

Mild Cognitive Impairment (MCI) is a condition characterized by cognitive deterioration greater than what is expected from normal aging, representing an important risk factor for the development of dementia. Early assessment of cognitive functions is therefore essential for promptly identifying any signs of decline. In addition to cognitive aspects, it is equally important to consider the possible psychopathological profile of patients, as such disorders can significantly influence the progression of the disease, quality of life, and the ability to manage daily activities. This protocol aims to explore the presence of psychopathological disorders in patients with MCI, with particular attention to their impact on awareness of cognitive deficits (anosognosia) and on the subjective perception of difficulties in daily life, especially in social and work contexts. The study seeks to outline a comprehensive picture of the psychopathological profile in patients with MCI, facilitating the identification of targeted and personalized interventions capable of improving clinical management and the overall well-being of the individual.

Study Overview

• Status: Not yet recruiting
• Conditions: Mild Cognitive Impairment (MCI)

Detailed Description

The study has a cross-sectional observational design, with data collected at a single time point (T0). The overall duration of the study, estimated at approximately 12 months, will depend on the time required to complete participant enrollment, data analysis, and dissemination of results. The purpose of this protocol is to investigate the presence of psychopathological disorders in patients with Mild Cognitive Impairment (MCI), with particular attention to their impact on awareness of cognitive deficits (anosognosia) and on the ability to cope with difficulties in social and work-related activities.

In this context, the study aims to outline a broader and more structured picture of the psychopathological profile of patients with MCI. This perspective will make it possible to analyze the interactions between emotional aspects, personality characteristics, and cognitive decline, with the goal of identifying more targeted and personalized intervention strategies capable of improving clinical management and promoting overall well-being.

The primary objective is to assess the presence of psychopathological disorders in patients with Mild Cognitive Impairment (MCI). The secondary objectives are to examine the impact of psychopathological disorders on the level of awareness of one's cognitive decline (partial or total anosognosia) and to evaluate how such disorders affect daily life by comparing the subjective perception of difficulties in social and work contexts.

As this is a cross-sectional observational study involving a single group of MCI patients, the sample size was estimated a priori using G*Power 3.1 with a one-sample binomial test (two-tailed) for the primary objective, the estimation of the prevalence of psychopathological disorders. Based on the literature, an expected prevalence of p1 = 0.20 was assumed, to be compared with a reference value of p2 = 0.32 (α = 0.05; power 1-β = 0.85), resulting in an estimated sample size of N = 118 subjects. Considering a 15% margin for possible drop-outs or invalid data, the final sample size was set at N = 136 participants.

Subjects will be included in the study if, based on available clinical documentation, they meet the following requirements: age between 50 and 72 years; diagnosis of Mild Cognitive Impairment (MCI), referred to the Neuropsychology Clinic for an initial evaluation or clinical follow-up; absence of behavioral, psychiatric, or sensory disorders severe enough to significantly compromise the performance of cognitive tests or the completion of questionnaires.

Subjects will be excluded from the study if clinical documentation reveals at least one of the following conditions: neurological disorders other than MCI, such as recent stroke, severe traumatic brain injury, epilepsy, multiple sclerosis, or other atypical neurodegenerative diseases; major psychiatric comorbidities not stabilized at the time of assessment (e.g., schizophrenia, bipolar disorder in an active phase, untreated severe depression); severe uncorrected sensory deficits (visual or auditory) that could compromise the validity of cognitive and functional assessments; use of medications with significant potential cognitive impact (e.g., sedatives, high-dose antipsychotics) not stabilized at the time of evaluation; terminal-stage internal or oncological diseases, or other medical conditions that significantly interfere with the performance of assessment procedures.

Each patient deemed eligible for the study will be informed about the study's purpose and will freely decide whether to participate. Only after the patient, or their Legal Representative, has agreed to participate in the study and signed the informed consent form may the Investigator proceed with the planned procedures.

The patient's pathway through the study will proceed as follows: clinical data for each subject will be shared through a secure database accessible to study collaborators using personal credentials. After verifying inclusion and exclusion criteria and obtaining informed consent, patients will proceed to the subsequent phases of the study.

1. Enrollment phase: verification of inclusion and exclusion criteria; collection of demographic data; collection of the subject's clinical history.
2. Assessment phase: eligible patients will undergo a battery of standardized tests aimed at assessing cognitive functioning, the presence of psychopathological traits, subjective awareness of deficits, and personal perception and ability to manage difficulties in daily activities. The battery will include the following instruments: Brief Cognitive Status Examination (BCSE) and/or Montreal Cognitive Assessment (MoCA), Minnesota Multiphasic Personality Inventory-3 (MMPI-3), Beck Depression Inventory (BDI-II), State-Trait Anxiety Inventory (STAI-Y), Cognitive Failures Questionnaire (CFQ), Social Functioning Questionnaire (SFQ), Instrumental Activities of Daily Living (IADL).

• Study Type: Observational
• Enrollment (Estimated): 118

Contacts and Locations

• Study Contact: Name: Irene Cappadona; Phone Number: +393274409990; Email: irene.cappadona@irccsme.it

Study Locations

• Italy
  • Me
    • Messina, Me, Italy, 98124
      • IRCCS Centro Neurolesi Bonino Pulejo

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult; Older Adult
• Accepts Healthy Volunteers: No

• Sampling Method: Non-Probability Sample

Study Population

As this is a cross-sectional observational study involving a single group of MCI patients, the sample size was estimated a priori using G*Power 3.1 with a one-sample binomial test (two-tailed) for the primary objective, namely the estimation of the prevalence of psychopathological disorders. In accordance with the literature, an expected prevalence of p1 = 0.20 was assumed and compared with a reference value of p2 = 0.32 (α = 0.05; power 1-β = 0.85), yielding an estimated sample size of N = 118 subjects. Considering a 15% margin for potential drop-outs or invalid data, the final sample size was set at N = 136 participants.

Description

Inclusion Criteria:

• Age between 50 and 72 years;
• Diagnosis of Mild Cognitive Impairment (MCI), with referral to the Neuropsychology clinic for an initial evaluation or for clinical monitoring;
• Absence of behavioral, psychiatric, or sensory disorders that could significantly compromise the performance of cognitive tests or the completion of questionnaires.

Exclusion Criteria:

• Neurological disorders other than MCI, such as recent stroke, severe traumatic brain injury, epilepsy, multiple sclerosis, or other atypical neurodegenerative diseases;
• Major psychiatric comorbidities not stabilized at the time of the assessment (e.g., schizophrenia, bipolar disorder in an active phase, untreated severe depression);
• Severe uncorrected sensory deficits (visual or hearing) capable of compromising the validity of cognitive and functional assessments;
• Use of medications with significant potential cognitive impact (e.g., sedatives, high-dose antipsychotics) not stabilized at the time of the assessment;
• Terminal-stage internal or oncological diseases, or other medical conditions that significantly interfere with the assessment procedures.

Study Plan

How is the study designed?

Number of groups / cohorts

1

Cohorts and Interventions

Group / Cohort
MCI; Patients diagnosed with Mild Cognitive Impairment

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Prevalence of psychopathological disorders in patients with MCI	The primary outcome variable is the presence of psychopathological disorders, assessed using the MMPI-3 test, which is used as an indicator of the psychopathological profile in patients with mild cognitive impairment.	12 months

Collaborators and Investigators

• Sponsor: IRCCS Centro Neurolesi Bonino Pulejo

Study record dates

Study Major Dates

• Study Start (Estimated): January 12, 2026
• Primary Completion (Estimated): January 12, 2027
• Study Completion (Estimated): January 12, 2027

Study Registration Dates

• First Submitted: January 14, 2026
• First Submitted That Met QC Criteria: January 14, 2026
• First Posted (Actual): January 22, 2026

Study Record Updates

• Last Update Posted (Actual): January 22, 2026
• Last Update Submitted That Met QC Criteria: January 14, 2026
• Last Verified: November 1, 2025

More Information

Terms related to this study

• Keywords: Cognitive decline; Neuropsychological assessment; Mild Cognitive Impairment (MCI); Anosognosia; Social functioning; Psychopathological disorders; Work functioning
• Additional Relevant MeSH Terms: Neurologic Manifestations; Nervous System Diseases; Mental Disorders; Neurobehavioral Manifestations; Neurocognitive Disorders; Cognition Disorders; Perceptual Disorders; Pathological Conditions, Signs and Symptoms; Behavior; Signs and Symptoms; Social Behavior; Cognitive Dysfunction; Agnosia; Social Adjustment
• Other Study ID Numbers: 11/2025

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No